BD’s new high-tech manufacturing facility in Zaragoza, Spain, will create up to 600 jobs by 2030.
BD (Becton, Dickinson and Company), a US-based medical technology company, announced on May 18, 2021 that it plans to build a €165 million (USD$200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030.
The new site will initially house a workforce of 150 people in an area of 8000 m2 (86,000 ft2), with the numbers eventually rising to 600 people in an area of 30,000 m2 (323,000 ft2) by 2030, BD said in a company press release. Construction of the fully-digital, eco-efficient site will begin in late 2021, making it the fourth BD manufacturing site in Spain.
"BD's new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in prefillable syringes, such as vaccines and other biologic drugs," said Eric Borin, worldwide president of BD Pharmaceutical Systems, in the press release. "This new plant will also add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the COVID-19 pandemic."
Source: BD
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.